The Challenge

Traditional healthcare models are predominantly reactive, often resulting in delayed interventions for conditions such as metabolic syndrome (MbS), which can lead to critical health issues like arteriosclerosis, heart attacks, and strokes.

 

The Solution

MiWear is at the forefront of a healthcare revolution, leveraging the power of miniaturized and cost-effective Mid-Infrared (MIR) Spectroscopy. This cutting-edge technology is designed for everyday use, capable of detecting MbS-related biomarkers in the skin's interstitial fluid, thereby facilitating ongoing health monitoring and empowering proactive healthcare decisions.

 

The MiWear Consortium - A Synergy of Expertise

 

MiWear proudly collaborates with a premier consortium, uniting diverse specialists from the realms of biomarkers, optical spectroscopy, laser physics, business, finance, and gender studies to pioneer a breakthrough in personal health monitoring:

Quantune: Spearheads the innovation with its trailblazing Mid-Infrared spectroscopy technology, making advanced biomarker measurement accessible to all.

Joanneum Research & Radboud University Medical Center: Offers unparalleled biomedicine, health sciences, and gender-specific symptomatology insights.

VTT Technical Research Center of Finland Ltd: Drives the development of MEMS components essential for the miniaturization of the spectrometer.

Artificial Intelligence Experts: Develops sophisticated AI models for spectrum analysis, enhancing the precision of medical diagnoses and treatments.

Science & Strategy SL: Focuses on translating health technologies into societal and economic benefits across the EU.

 

Together, we're not just envisioning the future of healthcare — we're creating it. MiWear represents a pivotal shift towards personalized, proactive health management, promising a healthier future for individuals and communities worldwide.